基于人工智能的巨核细胞形态指纹识别:评估MPN患者疾病的新工具
该研究开发了一种机器学习方法,对反应性/非肿瘤性骨髓活检样本(n=43)及确诊为原发性血小板增多症(n=45)、真性红细胞增多症(n=18)或骨髓纤维化(n=25)患者的骨髓活检样本中的巨核细胞特征进行自动识别、定量分析和抽象表示,组织诊断MPN的预测准确度高(曲线下面积=0.95),并显示出区分重要MPN亚型的潜力。
要点
- 机器学习可自动识别并定量分析骨髓活检中的巨核细胞特征。
- 该方法组织诊断MPN的曲线下面积为0.95。
- 该方法有潜力作为标准遗传和分子检测的辅助手段。
核心结论
- 自动骨髓活检表型分析方法在确诊或疑似MPN患者中具有作为标准遗传和分子检测辅助手段的显著潜力,可作为常规诊断路径的一部分或用于评估疾病进展/治疗反应。
研究设计与样本
- 研究使用反应性/非肿瘤性骨髓活检样本(n=43)以及确诊为原发性血小板增多症(n=45)、真性红细胞增多症(n=18)或骨髓纤维化(n=25)患者的样本,开发了一种机器学习方法用于巨核细胞特征的自动识别、定量分析和抽象表示。
主要发现
- 该方法组织诊断MPN的预测准确度高(曲线下面积=0.95)。
- 研究结果揭示了区分重要MPN亚型的明确证据。
- 在分析的患者队列背景下可视化呈现抽象巨核细胞特征的方法,以超越常规方法的方式促进了样本的解释和监测。
关键数值与推荐
- 组织诊断MPN的曲线下面积=0.95。
临床怎么用
- 自动骨髓活检表型分析方法可作为标准遗传和分子检测的辅助手段,用于确诊或疑似MPN患者,作为常规诊断路径的一部分或用于评估疾病进展/治疗反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accurate diagnosis and classification of myeloproliferative neoplasms (MPNs) requires integration of clinical, morphological, and genetic findings. Despite major advances in our understanding of the molecular and genetic basis of MPNs, the morphological assessment of bone marrow trephines (BMT) is critical in differentiating MPN subtypes and their reactive mimics. However, morphological assessment is heavily constrained by a reliance on subjective, qualitative, and poorly reproducible criteria. To improve the morphological assessment of MPNs, we have developed a machine learning approach for the automated identification, quantitative analysis, and abstract representation of megakaryocyte features using reactive/nonneoplastic BMT samples (n = 43) and those from patients with established diagnoses of essential thrombocythemia (n = 45), polycythemia vera (n = 18), or myelofibrosis (n = 25). We describe the application of an automated workflow for the identification and delineation of relevant histological features from routinely prepared BMTs. Subsequent analysis enabled the tissue diagnosis of MPN with a high predictive accuracy (area under the curve = 0.95) and revealed clear evidence of the potential to discriminate between important MPN subtypes. Our method of visually representing abstracted megakaryocyte features in the context of analyzed patient cohorts facilitates the interpretation and monitoring of samples in a manner that is beyond conventional approaches. The automated BMT phenotyping approach described here has significant potential as an adjunct to standard genetic and molecular testing in established or suspected MPN patients, either as part of the routine diagnostic pathway or in the assessment of disease progression/response to treatment.
引用
- Sirinukunwattana K, Aberdeen A, Theissen H, et al. Artificial intelligence-based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients. Blood Adv. 2020. PMID: 32706893. doi:10.1182/bloodadvances.2020002230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。